Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|September 19, 2017
Leistritz to Host Annual Twin Screw Extrusion Workshop
Author(s)Pharmaceutical Technology Editors
Leistritz’s Twin Screw Extrusion Workshop will take place on Nov. 29–30, 2017 in both Clifton, NJ and the NJ Leistritz facility, and will feature classroom sessions and equipment demonstrations.
Advertisement
Leistritz announced its annual Twin Screw Extrusion Workshop happening Nov. 29–30, 2017. The event will feature classroom sessions taking place at the Holiday Inn in Clinton, NJ and equipment demonstrations at the company’s NJ-based process laboratory.
Classroom topics include the following:
- Co-rotating and counter-rotating twin screw extrusion technology
- Screw design and process techniques
- Techniques for dispersive and/or distributive mixing
- Devolatilization process techniques and practices
- Scale-up of the twin screw extrusion process
- Feeder and material handling for pellets, powders and liquids
- Die and downstream system technologies
- Process troubleshooting
- Screw assembly and disassembly
- Twin screw extruder maintenance tips and procedures.
The workshop demonstrations at the process laboratory will cover the following topics:
- Co-rotating and counter-rotating twin screw extruders
- Devolatilization via extrusion: ambient, vacuum assist, and multi-stage
- Downstream addition of fillers, fibers and additives
- Direct sheet/film extrusion with gear pump front-end
- Foam extrusion via supercritical injection.
The workshop will also include industry and academia contributions.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement